BioMarin has set the price for its newly approved drug Vimizim, a treatment for Moquito A syndrome, at $380,000 per year. At that price, it expects to garner about $500 M in annual sales and the drug clocks in with the 3rd highest overall drug price.
Orphan drugs, typically for very small patient populations, hold all the top spots for highest priced drugs. The top 5 are listed below:
- Alexion Pharmaceuticals, Soliris, paroxysmal nocturnal hemoglobinuria, $440,000
- ViroPharma, Cinryze, familial hypercholesterolemia, $415,000
- BioMarin, Vimizim, Morquito A syndrome, $380,000
- Shire, Elaprase, Hunter Syndrome, $375,000
- BioMarin, Naglazyme, Maroteaux-Lamy syndrome, $375,000
All of these drugs achieve sales between $500 M and $2 B annually which helps make the orphan drug area attractive now to biopharmaceutical companies. Not surprisngly, it also makes the companies themselves attractive targets for acquisition rumors as all 4 above have been prominently mentioned by various analysts and industry pundits. See Fierce Pharma.
Posted by Bruce Lehr Feb 20th 2014.